Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International publ : DiviTum - Strong prognostic marker in operable breast cancer

11/20/2019 | 02:21am EST

Uppsala, Sweden, November 20, 2019. Biovica, active in cancer biomarkers, today announced clinical data that demonstrate DiviTum as a strong prognostic marker in operable breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium, SABCS, December 10-14, 2019, the world's largest scientific congress focusing on breast cancer.

The study is a retrospective analysis on serum samples from a randomized clinical trial comprising 644 women with operable breast cancer (premenopausal with stage II-IIIB HR+ breast cancer). Serum samples were collected pre-operatively on the day of surgery.

After five years, patients with low pre-operative DiviTum values (the lowest quartile, <25 percent) showed a disease-free survival rate of 81 percent versus 58 percent in the group with the highest DiviTum values (>75 percent).

"We are thrilled to see these new, interesting results. It demonstrates that pre-operative DiviTum values measured in serum is a strong prognostic marker in operable breast cancer with a potential to identify patients with the most aggressive tumors in order to personalize their therapy," said lead investigator Dr. Luca Malorni, Prato Hospital, Italy.

DiviTum measures thymidine kinase activity (TKa), an established marker of cancer cell proliferation, but until now there has been limited data regarding the role of TKa as a prognostic biomarker in operable breast cancer.

"Dr Malorni's research group has managed to show prognostic effect in a large cohort of women with operable breast cancer. This gives us high expectations on DiviTum's potential beyond monitoring of treatment for patients with metastatic breast cancer, which is our first application for DiviTum." said Anders Rylander, CEO of Biovica.

The title of the poster (P5-06-11) at San Antonio Breast Cancer Symposium is Serum thymidine kinase-1 activity (TKa) as a prognostic marker in premenopausal women with hormone receptor positive (HR+) operable breast cancer (BC).

For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
email: anders.rylander@biovica.com

Biovica - Best Treatment from Day One.
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medicines Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.

https://news.cision.com/biovica-international-ab/r/biovica-s-divitum---strong-prognostic-marker-in-operable-breast-cancer,c2968655

https://mb.cision.com/Main/14910/2968655/1147279.pdf

https://news.cision.com/biovica-international-ab/i/2p5a1898-color-shader,c2718392

(c) 2019 Cision. All rights reserved., source Press Releases - English

All news about BIOVICA INTERNATIONAL AB (PUBL)
2020BIOVICA INTERNATIONAL : carries out a directed share issue of Class B shares and..
AQ
2020BIOVICA INTERNATIONAL : intends to carry out a directed share issue of Class B s..
AQ
2020BIOVICA INTERNATIONAL : successfully completes clinical validation for DiviTum® ..
AQ
2020BIOVICA INTERNATIONAL PUBL : Notice to AGM for Biovica International AB
AQ
2020BIOVICA INTERNATIONAL AB : – Annual Report for the fiscal year 2019/2020 p..
AQ
2020BIOVICA INTERNATIONAL PUBL : completes analytical validation as part of FDA appl..
AQ
2020Biovica Year-end Report for 2019/2020
AQ
2020BIOVICA INTERNATIONAL PUBL : DiviTum® acknowledged in ASCO educational book
AQ
2020BIOVICA INTERNATIONAL PUBL : DiviTum® and TK activity acknowledged in highly ren..
AQ
2020BIOVICA INTERNATIONAL PUBL : provides market share target at today's Capital Mar..
AQ
More news
Financials
Sales 2021 3,00 M 0,36 M 0,36 M
Net income 2021 -38,5 M -4,65 M -4,65 M
Net cash 2021 134 M 16,1 M 16,1 M
P/E ratio 2021 -32,3x
Yield 2021 -
Capitalization 1 272 M 153 M 154 M
EV / Sales 2021 380x
EV / Sales 2022 26,7x
Nbr of Employees 21
Free-Float 75,2%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 67,00 SEK
Last Close Price 45,00 SEK
Spread / Highest target 129%
Spread / Average Target 48,9%
Spread / Lowest Target -31,1%
EPS Revisions
Managers and Directors
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOVICA INTERNATIONAL AB (PUBL)-12.11%153
EXACT SCIENCES CORPORATION13.22%23 854
GUARDANT HEALTH, INC.24.08%15 988
INVITAE CORPORATION32.05%10 889
BGI GENOMICS CO., LTD.38.46%10 879
ADAPTIVE BIOTECHNOLOGIES CORPORATION14.56%9 265